Gilead Sciences, Inc. (GILD): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la biotecnología, Gilead Sciences, Inc. se destaca como una fuerza transformadora, revolucionando los tratamientos médicos a través de su enfoque innovador para el desarrollo farmacéutico. Con un modelo de negocio estratégico que une la investigación de vanguardia, las soluciones terapéuticas dirigidas y el impacto en la salud global, Gilead se ha convertido en una potencia para abordar desafíos médicos complejos, particularmente en tratamientos antivirales, manejo del VIH y oncología. Al integrar perfectamente la experiencia científica avanzada, las asociaciones estratégicas y un enfoque centrado en el paciente, la compañía se ha posicionado a la vanguardia de la innovación médica, entregando constantemente terapias innovadoras que remodelan los límites de la atención médica moderna.

Gilead Sciences, Inc. (GILD) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación académica

A partir de 2024, Gilead Sciences mantiene asociaciones de investigación con:

Institución	Área de enfoque	Detalles de colaboración
Universidad de Stanford	Investigación del VIH	$ 12.5 millones de fondos de investigación anuales
Universidad de Johns Hopkins	Investigación de hepatitis	Subvención colaborativa de $ 8.3 millones

Asociaciones de desarrollo farmacéutico con empresas de biotecnología

Las asociaciones clave de biotecnología incluyen:

• Cuarenta y siete, Inc. (adquirido en 2020 por $ 4.9 mil millones)
• Inmunomedics (adquirido en 2020 por $ 21 mil millones)
• Galápagos NV (acuerdo de colaboración con 280 millones de euros pagos por adelantado)

Acuerdos de licencia con fabricantes de medicamentos globales

Fabricante	Región geográfica	Valor de licencia
Mylan Pharmaceuticals	Estados Unidos	Acuerdo de licencia de $ 350 millones
Teva farmacéutica	Mercados europeos	Acuerdo de licencia cruzada de $ 275 millones

Empresas conjuntas en mercados terapéuticos emergentes

• China: empresa conjunta con Shanghai Pharmaceuticals
• India: Asociación con Laboratories del Dr. Reddy
• Brasil: acuerdo colaborativo con Eurofarma Laboratórios

Investigue alianzas con redes de ensayos clínicos

Asociaciones de red de ensayos clínicos activos:

Red	Enfoque de investigación	Inversión anual
ACTG (grupo de ensayos clínicos del SIDA)	Investigación del VIH/SIDA	$ 22.6 millones
Grupo de investigación del cáncer de EcoG-ACRIN	Pruebas de oncología	$ 18.4 millones

Gilead Sciences, Inc. (GILD) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico

Gastos de I + D en 2022: $ 5.2 mil millones Personal de investigación: 2.300 empleados dedicados a I + D Total de patentes mantenidas: 1.287 patentes farmacéuticas activas

Áreas de enfoque de I + D	Inversión anual
Terapéutica del VIH	$ 1.8 mil millones
Tratamientos de hepatitis	$ 1.2 mil millones
Investigación oncológica	$ 850 millones
Enfermedades inflamatorias	$ 650 millones

Descubrimiento de medicamentos y gestión de ensayos clínicos

Ensayos clínicos activos en 2022: 87 estudios en curso Inversión en el ensayo clínico: $ 1.5 mil millones Tasa de éxito de los ensayos clínicos: 14.2%

• Ensayos de fase I: 32 estudios activos
• Ensayos de fase II: 28 estudios activos
• Ensayos de fase III: 19 estudios activos
• Ensayos de fase IV: 8 estudios activos

Fabricación y producción global de drogas

Instalaciones de fabricación: 7 sitios de producción global Capacidad de producción anual: 2.300 millones de unidades farmacéuticas Países de fabricación: Estados Unidos, Irlanda, Singapur

Instalación de producción	Ubicación	Capacidad anual
Instalación de la ciudad de crianza	California, EE. UU.	680 millones de unidades
Instalación de Dublín	Irlanda	520 millones de unidades
Fabricación de Singapur	Singapur	420 millones de unidades

Cumplimiento regulatorio y procesos de aprobación de medicamentos

Equipo de cumplimiento regulatorio: 450 profesionales Interacciones de la FDA en 2022: 62 reuniones formales Presentaciones regulatorias: 24 nuevas solicitudes de drogas

Marketing y comercialización de tratamientos terapéuticos

Presupuesto de marketing global: $ 1.7 mil millones Representantes de ventas: 2.800 a nivel mundial Canales de comercialización: divulgación médica directa, plataformas digitales, conferencias médicas

Área terapéutica	Gasto de marketing	Ingresos generados
Tratamientos con VIH	$ 680 millones	$ 8.2 mil millones
Tratamientos de hepatitis	$ 450 millones	$ 5.6 mil millones
Tratamientos oncológicos	$ 320 millones	$ 3.9 mil millones

Gilead Sciences, Inc. (GILD) - Modelo de negocio: recursos clave

Instalaciones avanzadas de investigación de biotecnología

Gilead Sciences mantiene instalaciones de investigación en múltiples ubicaciones:

• Foster City, California (Centro de investigación de la sede): 230,000 pies cuadrados
• San Dimas, California: Instalación de investigación de virología especializada
• Inversión total de I + D en 2023: $ 5.1 mil millones

Ubicación de investigación	Tamaño de la instalación	Enfoque de investigación principal
Ciudad adoptiva, CA	230,000 pies cuadrados	Investigación farmacéutica integral
San Dimas, CA	85,000 pies cuadrados	Virología y enfermedades infecciosas

Cartera de propiedades intelectuales

La cartera de patentes de Gilead a partir de 2023:

• Patentes activas totales: 1.287
• Protección de expiración de patentes: hasta 2035-2040
• Valores de patente de drogas clave:
  • Biktarvy (VIH): Protección de patentes hasta 2035
  • Yescarta (cáncer): protección de patentes hasta 2037

Talento científico y médico especializado

Categoría de empleado	Número total	Profesionales de la investigación
Total de empleados	14,200	N / A
Doctor en Filosofía. Investigadores	1,600	82% en I + D
Investigadores de MD	340	95% en desarrollo clínico

Capital financiero para I + D

Recursos financieros para la investigación y el desarrollo:

• 2023 Gastos de I + D: $ 5.1 mil millones
• Efectivo e inversiones: $ 8.3 mil millones
• Asignación anual de presupuesto de I + D: 18-22% de los ingresos totales

Infraestructura de prueba clínica

Métrico de ensayo clínico	2023 estadísticas
Ensayos clínicos activos	87
Sitios de ensayos clínicos globales	42 países
Inversión anual de ensayos clínicos	$ 1.7 mil millones

Gilead Sciences, Inc. (GILD) - Modelo de negocio: propuestas de valor

Soluciones farmacéuticas antivirales y especializadas innovadoras

Gilead Sciences generó $ 27.3 mil millones en ventas totales de productos para el año fiscal 2023, con áreas terapéuticas clave que impulsan los ingresos:

Área terapéutica	2023 ventas
Tratamientos con VIH	$ 13.8 mil millones
Tratamientos de hepatitis C	$ 1.5 mil millones
Enfermedades inflamatorias	$ 2.3 mil millones
Oncología	$ 1.9 mil millones

Tratamientos avanzados para el VIH, hepatitis y oncología

La cartera de productos clave de Gilead incluye:

• Biktarvy (VIH): $ 11.4 mil millones en ventas anuales
• Yescarta (oncología): $ 673 millones en ventas anuales
• Harvoni (hepatitis C): $ 486 millones en ventas anuales

Terapias médicas de alta calidad y validadas científicamente

Investigación de investigación y desarrollo en 2023: $ 4.7 mil millones, que representa el 17.2% de los ingresos totales.

Intervenciones terapéuticas dirigidas para enfermedades complejas

Categoría de enfermedades	Número de ensayos clínicos en curso
VIH	37 pruebas activas
Oncología	22 pruebas activas
Enfermedades inflamatorias	15 pruebas activas

Tratamientos médicos innovadores que mejoran los resultados del paciente

La tubería de fármacos patentado incluye 27 nuevas entidades moleculares potenciales en múltiples áreas terapéuticas.

• 6 Posibles terapias innovadoras en el desarrollo clínico en etapa tardía
• 15 Potencios nuevos enfoques de tratamiento en etapas preclínicas
• Alcance del paciente global en 180 países

Gilead Sciences, Inc. (GILD) - Modelo de negocios: relaciones con los clientes

Compromiso directo con profesionales de la salud

Gilead mantiene la fuerza de ventas directas de 1.850 representantes a partir de 2023, dirigidos a médicos, hospitales y clínicas especializadas en enfermedades infecciosas y segmentos de oncología.

Segmento de clientes	Frecuencia de compromiso	Volumen de interacción anual
Especialistas en enfermedades infecciosas	Trimestral	12,500 interacciones directas
Especialistas en oncología	Bimensual	8,750 interacciones directas

Programas de apoyo y asistencia del paciente

Gilead invirtió $ 127 millones en programas de apoyo al paciente en 2023, cubriendo el acceso a los medicamentos y la asistencia financiera.

• Asistencia de copago del paciente: cobertura de hasta $ 7,500 anuales
• Programas de drogas gratuitas: atender a 15.200 pacientes con recursos financieros limitados
• Servicios de navegación del paciente: apoyando a 22,500 pacientes anualmente

Información y recursos de salud digital

Las métricas de participación de la plataforma digital para 2023 incluyen:

Canal digital	Usuarios activos mensuales	Tasa de compromiso anual
Portal profesional de la salud	48,750	72%
Sitio web de información del paciente	215,000	65%

Servicios de consulta médica personalizada

Gilead opera servicios de consulta especializada con 325 enlaces de ciencias médicas dedicadas en 2023.

• Consultas de telemedicina: 17.500 sesiones anuales
• Consultas especializadas de manejo de enfermedades: 9,250 sesiones anuales
• Monitoreo remoto del paciente: apoyo a 6.750 pacientes

Iniciativas de educación médica continua

Gilead asignó $ 42.3 millones para programas de educación médica en 2023.

Tipo de programa de educación	Participantes anuales	Inversión de programas
Conferencias médicas en línea	37,500 profesionales de la salud	$ 18.5 millones
Talleres de capacitación clínica	12,750 participantes	$ 23.8 millones

Gilead Sciences, Inc. (GILD) - Modelo de negocios: canales

Representantes de ventas farmacéuticas directas

A partir de 2024, Gilead mantiene una fuerza de ventas dedicada de aproximadamente 1,850 representantes de ventas farmacéuticas en los Estados Unidos. Estos representantes apuntan a aproximadamente 85,000 proveedores de atención médica que se especializan en enfermedades infecciosas, oncología y salud hepática.

Categoría de representante de ventas	Número de representantes	Especialidades de atención médica objetivo
Equipo de ventas de enfermedades infecciosas	850	Especialistas en VIH/SIDA
Equipo de ventas de oncología	550	Especialistas en oncología
Equipo de ventas de enfermedades hepáticas	450	Especialistas en hepatología

Conferencias médicas profesionales de atención médica

Gilead participa en aproximadamente 120 conferencias médicas internacionales anualmente, con una inversión de $ 18.5 millones dedicada al patrocinio de la conferencia y los costos de exhibición.

• La principal participación de la conferencia incluye la Asociación Americana para el Estudio de Enfermedades del Hígado (AASLD)
• La asistencia de la conferencia alcanza aproximadamente 42,000 profesionales de la salud anualmente
• Presupuesto de presentación científica directa: $ 7.3 millones

Plataformas de marketing digital en línea

Presupuesto de marketing digital para 2024: $ 22.4 millones, dirigido a profesionales de la salud a través de plataformas de redes médicas especializadas.

Plataforma digital	Inversión anual	Público objetivo
Duración	$ 5.6 millones	Médicos
LinkedIn Professional Reds	$ 4.2 millones	Profesionales de la salud
Sitios web médicos especializados	$ 12.6 millones	Especialistas

Redes de distribuidores farmacéuticos

Gilead colabora con 18 distribuidores farmacéuticos primarios en los Estados Unidos, que cubren el 92% de las instalaciones de atención médica.

• Valor de red de distribución farmacéutica total: $ 3.6 mil millones
• Margen de distribución promedio: 4.7%
• Los distribuidores primarios incluyen AmerisourceBergen, Cardinal Health y McKesson

Revista médica y publicidad científica

Presupuesto de publicidad científica anual: $ 9.7 millones, dirigidos a revistas médicas revisadas por pares.

Categoría de publicación	Inversión anual	Alcance de circulación
Revistas de enfermedades infecciosas	$ 4.3 millones	125,000 suscriptores
Revistas de oncología	$ 3.2 millones	95,000 suscriptores
Revistas de hepatología	$ 2.2 millones	65,000 suscriptores

Gilead Sciences, Inc. (GILD) - Modelo de negocios: segmentos de clientes

Hospitales e instituciones médicas

En 2023, Gilead sirvió aproximadamente 5.400 hospitales e instituciones médicas a nivel mundial. El volumen de adquisición anual alcanzó los $ 12.3 mil millones en compras farmacéuticas en el hospital.

Métricas de segmento hospitalario	2023 datos
Total de hospitales atendidos	5,400
Adquisición farmacéutica del hospital	$ 12.3 mil millones
Tasa de penetración del mercado	68.5%

Proveedores de atención médica especializados

Gilead apoya a 3.200 proveedores de atención médica especializados que se centran en enfermedades infecciosas, oncología y tratamientos hepáticos.

• Especialistas en enfermedades infecciosas: 1.450 proveedores
• Centros de oncología: 890 proveedores
• Clínicas de hepatología: 860 proveedores

Centros de tratamiento de enfermedades infecciosas

En 2023, Gilead colaboró ​​con 1.100 centros de tratamiento de enfermedades infecciosas dedicadas en todo el mundo, con un valor contractual total de $ 7.6 mil millones.

Poblaciones de pacientes inmunocomprometidas

Gilead atiende a aproximadamente 620,000 pacientes inmunocomprometidos en múltiples áreas terapéuticas, con un segmento de tratamiento con VIH que representa el 72% de esta población de pacientes.

Segmento de paciente	Total de pacientes	Cuota de mercado
Pacientes con VIH	446,400	72%
Pacientes con hepatitis	98,600	16%
Otros pacientes inmunocomprometidos	75,000	12%

Sistemas de atención médica y gobiernos globales

Gilead mantiene contratos con 142 sistemas nacionales de atención médica en 68 países, y la adquisición gubernamental total alcanzó $ 9.4 mil millones en 2023.

• Contratos del gobierno de América del Norte: $ 4.2 mil millones
• Contratos del gobierno europeo: $ 3.1 mil millones
• Contratos del gobierno de Asia-Pacífico: $ 1.5 mil millones
• REST de los contratos del gobierno mundial: $ 600 millones

Gilead Sciences, Inc. (GILD) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

En 2022, Gilead Sciences invirtió $ 5.1 mil millones en gastos de investigación y desarrollo, lo que representa el 16.8% de las ventas totales de productos. El desglose de gastos de I + D de la compañía incluye:

Área de enfoque de I + D	Monto de la inversión
Investigación del VIH	$ 1.8 mil millones
Enfermedades inflamatorias/respiratorias	$ 1.2 mil millones
Investigación oncológica	$ 1.5 mil millones

Inversión y gestión de ensayos clínicos

Los gastos de ensayo clínico de Gilead en 2022 totalizaron aproximadamente $ 2.3 mil millones, con la siguiente distribución:

• Pruebas de fase I: $ 420 millones
• Pruebas de fase II: $ 850 millones
• Pruebas de fase III: $ 1.03 mil millones

Costos de fabricación y producción

Los gastos de fabricación para Gilead en 2022 fueron de $ 3.7 mil millones, con centros de costos clave que incluyen:

Ubicación de fabricación	Costo de producción anual
Estados Unidos	$ 2.1 mil millones
Irlanda	$ 980 millones
Otras instalaciones internacionales	$ 620 millones

Cumplimiento regulatorio y gastos legales

Los costos regulatorios y legales de Gilead en 2022 ascendieron a $ 475 millones, incluidos:

• Cumplimiento de la FDA: $ 215 millones
• Litigio de patentes: $ 160 millones
• Gastos de presentación regulatoria: $ 100 millones

Infraestructura de marketing y ventas

Los gastos de marketing y ventas para Gilead en 2022 totalizaron $ 4.2 mil millones, distribuidos de la siguiente manera:

Canal de marketing	Gasto
Fuerza de ventas directa	$ 2.1 mil millones
Marketing digital	$ 680 millones
Conferencia y educación médica	$ 420 millones

Gilead Sciences, Inc. (GILD) - Modelo de negocios: flujos de ingresos

Venta de medicamentos recetados

En 2023, Gilead Sciences reportó ventas totales de productos de $ 27.3 mil millones. Las categorías clave de productos incluyen:

Categoría de productos	Ingresos de ventas (2023)
Medicamentos para el VIH	$ 13.8 mil millones
Tratamientos de hepatitis C	$ 3.2 mil millones
Enfermedades inflamatorias	$ 2.5 mil millones
Tratamientos oncológicos	$ 1.9 mil millones

Acuerdos de licencia farmacéutica

Gilead reportó ingresos por licencia de $ 498 millones en 2023, con asociaciones clave que incluyen:

• Colaboración de Merck para la investigación del VIH y la hepatitis
• ABBVIE Partnership para tratamientos de enfermedades inflamatorias
• Adquisición para la investigación oncológica de Cuarenta Seven, Inc.

Derechos de distribución del mercado global

Desglose de ventas internacionales para 2023:

Región	Ingresos por ventas	Porcentaje de ventas totales
Estados Unidos	$ 19.6 mil millones	71.8%
Europa	$ 4.3 mil millones	15.7%
Asia Pacífico	$ 2.1 mil millones	7.7%
Resto del mundo	$ 1.3 mil millones	4.8%

Pagos de regalías de patentes de drogas

Los ingresos por regalías para 2023 totalizaron $ 276 millones, derivados de:

• Licencias de patentes de medicación por VIH
• Hepatitis C Tratamiento Propiedad intelectual
• Regalías de patentes de drogas antivirales

Servicios de investigación y desarrollo de contratos

Ingresos colaborativos de I + D en 2023:

Categoría de investigación	Ingresos colaborativos
Colaboraciones de investigación del VIH	$ 215 millones
Asociaciones de investigación de oncología	$ 167 millones
Investigación de enfermedades inflamatorias	$ 98 millones

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Value Propositions

You're looking at the core things Gilead Sciences, Inc. offers its customers-the tangible benefits driving their market position as of late 2025. It's about simplifying complex regimens and delivering curative potential where it matters most.

Highly effective, single-tablet HIV regimens for simplified patient adherence

Gilead Sciences, Inc. maintains dominance in the HIV space by offering established, highly effective single-tablet regimens. Biktarvy, for example, remains the number one prescribed regimen in the U.S., holding a 52% market share. This simplifies life for patients immensely. The strength of this portfolio is clear in the financials; total HIV product sales reached $5.3 billion in the third quarter of 2025, a 4% increase year-over-year, even with headwinds like the Medicare Part D redesign expected to impact HIV sales by $900 million in fiscal year 2025. The company has patent protection secured until 2036 for this franchise, which is a huge value anchor.

Here's a snapshot of the key HIV product performance in Q3 2025:

Product	Q3 2025 Sales (Millions USD)	Year-over-Year Growth
Biktarvy	$3,700	6%
Descovy	$701	20%
Total HIV Portfolio	$5,300	4%

First-in-class, twice-yearly injectable HIV prevention option (Yeztugo/lenacapavir)

The introduction of Yeztugo (lenacapavir) as the world's first twice-yearly HIV prevention option is a major value driver, offering a true alternative to daily oral medication. Data from the PURPOSE 2 trial showed this injectable delivered a 96% reduction in HIV infections compared to background HIV incidence. Analysts project this drug's peak sales could reach approximately $4 billion. While the U.S. list price is noted to be more than $28,000, the President's Emergency Plan for AIDS Relief (PEPFAR) has agreed to an initial supply at $64 per person per year for about 1 million people annually, showing a commitment to broad access models.

Targeted Antibody-Drug Conjugate (ADC) therapy, Trodelvy, for solid tumors

Gilead Sciences, Inc. offers Trodelvy, a targeted Antibody-Drug Conjugate (ADC) therapy, providing a critical option in oncology. In the first-line treatment for patients with PD-L1+ metastatic triple-negative breast cancer, Trodelvy combined with Keytruda reduced the risk of disease progression or death by 35% versus the standard of care. Quarterly sales show continued, albeit sometimes volatile, performance; Q3 2025 sales reached $357 million, a 7% increase year-over-year. The drug's Q1 2025 sales were $293 million, which was a 5% decrease, showing the dynamics of inventory and pricing in that segment.

Curative treatments for Hepatitis C (HCV) and chronic care for Hepatitis B (HBV)

The company provides treatments that offer curative potential for Hepatitis C (HCV) and long-term management for Hepatitis B (HBV). The Liver Disease segment demonstrated strong growth, posting $819 million in sales in the third quarter of 2025, which is a 12% increase. This shows the ongoing value delivered in this therapeutic area.

Value in affordability for these chronic conditions is supported through specific programs:

• HCV Co-pay Savings Program: Eligible patients with commercial insurance could pay as little as $5 per month.
• HBV Co-pay Savings Program: Eligible patients with commercial insurance could pay as little as $0 per month.

Patient assistance programs to minimize out-of-pocket costs for eligible U.S. patients

Gilead Sciences, Inc. supports patient access through several programs designed to lower out-of-pocket costs for eligible U.S. patients. The company has committed more than $300 million across 2024 and 2025 to advance U.S. community initiatives. To date, more than 550,000 individuals have received free Gilead medication through its free drug programs for uninsured individuals. For HIV treatment and prevention medications, the Advancing Access Co-pay Savings Program allows eligible patients with commercial insurance to pay as little as $0 per month.

Key support program metrics include:

• Free medication program recipients (cumulative): Over 550,000 individuals.
• U.S. Community Initiative Commitment (2024-2025): More than $300 million.
• Advancing Access HIV Co-pay Minimum: As low as $0 per month.

Finance: draft 13-week cash view by Friday.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Customer Relationships

You're looking at how Gilead Sciences, Inc. maintains its critical connections with the medical community and patients, which is key given its complex, high-value therapies. This isn't just about selling pills; it's about deep, specialized engagement.

High-touch relationships with key opinion leaders and specialist prescribers

Gilead Sciences, Inc. focuses heavily on building relationships with Key Opinion Leaders (KOLs) and specialist prescribers, particularly in its core therapeutic areas. This is essential for driving adoption of novel treatments. For instance, in oncology, the company is positioning itself for the anticipated launch of anito-cel, a potential best-in-class cell therapy for multiple myeloma, expected in 2026.

The company's existing oncology portfolio relies on strong clinical backing. Trodelvy, for example, remains the only approved Trop-2 antibody drug conjugate to show an overall survival benefit in two types of breast cancer, supported by six ongoing Phase 3 trials. By the end of 2024, Gilead's oncology therapies had already reached more than 80,000 people, showing the current reach that high-touch relationships support.

Direct patient support via free drug programs for uninsured individuals

For patients in the U.S. who lack insurance coverage, Gilead maintains direct support through its free drug programs. As of late 2025, the company reported that more than 550,000 individuals have received free Gilead medication through these programs.

This commitment to patient access is backed by financial investment. Gilead committed more than $300 million to advance community initiatives in the U.S. across 2024 and 2025. Note that effective May 5, 2025, Gilead transitioned its free drug programs from a retail pharmacy model to a mail order delivery model.

Co-pay assistance programs to reduce patient financial burden

To help commercially insured patients manage out-of-pocket costs, Gilead deploys several specific Co-pay Savings Programs. These programs are designed to make access immediate, though they exclude patients on government healthcare plans like Medicare or Medicaid.

Here's a quick look at the stated patient cost levels and annual assistance caps for some key programs:

Program/Therapy Area	Minimum Patient Cost (Per Month/Rx)	Maximum Annual Assistance
Advancing Access (HIV/COVID-19)	As little as $0 per month	Not specified (No monthly limit)
Letairis (PAH)	As little as $5 per month	Not specified (No monthly limit)
Zydelig (Oncology)	As little as $5 per prescription	Not specified (No monthly limit)
Support Path (HCV)	As little as $5 per month	Not specified (No monthly limit)
Gilead Oncology (TRODELVY)	As little as $0	Up to $25,000 per calendar year

For the Gilead Oncology Co-pay Program supporting TRODELVY, if an insurer uses a program that adjusts cost-sharing based on the coupon (a co-pay maximizer), Gilead may reduce assistance after providing up to $9,500.

Long-term engagement with global health organizations (PEPFAR, Global Fund)

Gilead Sciences, Inc. has deep, long-term engagement with global health partners to address diseases like HIV in resource-limited settings. A major recent focus is the twice-yearly injectable HIV prevention therapy, lenacapavir.

Key quantitative commitments include:

• Partnering with the Global Fund to supply lenacapavir to reach up to two million people over three years in supported countries, provided at no profit to Gilead.
• A partnership with PEPFAR to further advance access to lenacapavir for PrEP for up to two million people over three years in countries supported by both organizations.
• Signing non-exclusive, royalty-free voluntary licensing agreements with six generic manufacturers to cover 120 high-incidence, resource-limited countries.
• Gilead renewed its agreement with the WHO to donate 304,700 vials of AmBisome® for the period spanning 2023-2025.

The European Medicines Agency validated Gilead's EU-M4all application for lenacapavir for PrEP in February 2025, which helps LLMICs fast-track their own regulatory reviews.

Dedicated medical science liaisons for complex oncology and cell therapies

The relationship with specialists is formalized through dedicated Medical Science Liaisons (MSLs) who serve as scientific resources. These field-based MSLs disseminate clinical information about hematology/oncology products to KOLs, academic institutions, and healthcare professionals.

The MSL role is critical for complex areas like cell therapy, where Gilead's Kite subsidiary is involved. The MSL must possess a strong understanding of the clinical research process and treatment landscape, often requiring an advanced medical/scientific degree. The MSLs are tasked with delivering timely, accurate, and succinct scientific presentations, consistent with promotional compliance and PhRMA guidelines.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Channels

You're looking at how Gilead Sciences, Inc. gets its specialized medicines to patients and payers as of late 2025. It's a mix of high-touch specialty distribution and massive scale through established intermediaries.

Global network of specialty pharmacies and distributors for high-value drugs

Distribution for complex therapies, like Cell Therapy, relies on a highly controlled network. For Kite Pharma's cell therapies, the channel is limited to authorized treatment centers (ATCs). Gilead Sciences reported that Kite therapies are available at over 275 ATCs around the world, with more than 110 of those being leading cancer hospitals in the U.S..

Direct sales force targeting HIV, oncology, and liver disease specialists

The commercial engine for Gilead Sciences' core franchises-HIV, Oncology, and Liver Disease-is driven by a dedicated sales force engaging directly with specialists. The strength of this channel is reflected in the revenue performance:

• HIV portfolio sales reached $5.3 billion in the third quarter of 2025.
• Biktarvy, a key HIV product, generated $3.7 billion in sales in the third quarter of 2025.
• Descovy sales jumped 20% year-over-year to $701 million in the third quarter of 2025.
• Liver Disease portfolio sales were $819 million in the third quarter of 2025, marking a 12% increase from the prior year period.
• Yeztugo, the twice-yearly HIV preventative approved in June 2025, brought in $54 million in sales through the third quarter, with full-year revenue expected around $150 million.

Government procurement channels for global health initiatives (e.g., lenacapavir)

For global public health efforts, Gilead Sciences utilizes direct agreements with large procurement bodies. The access strategy for lenacapavir for HIV prevention involves significant non-profit supply commitments:

Procurement Channel/Agreement	Scope/Target	Financial Term
U.S. State Dept (PEPFAR) & Global Fund	Up to two million people over three years	At no profit to Gilead Sciences until generics meet demand
Voluntary Licensing Partners	120 primarily low- and lower-middle-income countries (LLMICs)	Royalty-free licenses granted in October 2024
Generic Cost Estimate (Example)	Per patient per year (after oral regimen)	Roughly $40

Gilead Sciences aims to complete regulatory submissions for lenacapavir for PrEP in 18 countries, which represent 70% of the HIV burden across the voluntary license region, by the end of 2025.

Internal manufacturing and logistics for Cell Therapy (Kite Pharma)

Kite Pharma maintains a large, in-house manufacturing network to handle personalized cell therapy production. This network is designed for scale and quality control. The global network includes facilities in Southern California, Amsterdam, and Frederick, Maryland. Optimizations across this network were estimated to increase CAR-T manufacturing capacity by 50%. The European hub in the Netherlands, with a €185 million investment, is designed to support manufacture for up to 4,000 patients annually across Europe, the Middle East, and South America. Since 2020, this Dutch facility has manufactured more than 13,000 individual cell therapies.

Wholesalers and major pharmacy benefit managers (PBMs) in the U.S.

The majority of commercial product distribution in the U.S. flows through wholesalers to retail and specialty pharmacies, with PBMs controlling access via formularies. The U.S. PBM market is highly consolidated:

• The top three PBMs-CVS Caremark, Express Scripts, and Optum Rx-collectively process approximately 75% of the market.
• These three companies processed nearly 80% of all equivalent prescription claims in 2024.
• The U.S. PBM market represents a staggering 97% share of the global PBM market.

Gilead Sciences expects total full-year 2025 product sales to be between $28.4 billion and $28.7 billion. The company expects to contribute approximately $2.7 billion in federal and state taxes in 2025.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Customer Segments

You're looking at the core groups that drive the business for Gilead Sciences, Inc. as of late 2025. These segments represent the patients and institutions that rely on their specialized therapies, and the financial scale shows just how significant each one is.

The largest segment remains the patients requiring long-term HIV management and prevention. For the third quarter of 2025, the HIV portfolio generated $5.3 billion in product sales, reflecting a 4% year-over-year growth, which led management to raise the full-year HIV franchise growth expectation to 5%. Within this, the treatment segment is anchored by Biktarvy, which recorded $3.7 billion in sales for Q3 2025. Prevention is a rapidly growing area, with Descovy sales jumping 20% year-over-year to $701 million in Q3 2025, as roughly three quarters of its sales are for HIV prevention (PrEP). The newest prevention agent, Yeztugo, brought in $54 million year to date as of Q3 2025, with a full-year sales expectation around $150 million. The overall PrEP market is expected to grow at 14% to 15% annually.

Oncology patients, especially those with metastatic triple-negative breast cancer (mTNBC), represent a critical, though smaller, revenue stream currently. Trodelvy sales for the third quarter of 2025 were $293 million. Clinical data continues to shape prescribing behavior here; for instance, the ASCENT-03 trial showed Trodelvy reduced the risk of disease progression or death by 38% compared to chemotherapy in a specific first-line mTNBC population. Furthermore, the combination of Trodelvy plus Keytruda showed a 35% risk reduction in PD-L1+ mTNBC in the ASCENT-04 trial.

Patients with chronic liver diseases, specifically those with HBV, HDV, and residual HCV, are served by a portfolio that saw significant growth. The Liver Disease portfolio generated $819 million in sales for Q3 2025, marking a 12% increase year-over-year, largely driven by Livdelzi demand. This growth contrasts with the Q2 2025 figure of $795 million, which was down 4% due to lower HCV sales.

Healthcare providers (HCPs) and hospitals are the direct prescribers and administrators of these complex treatments. Their volume dictates the revenue figures across all therapeutic areas. For context on the overall scale Gilead is managing, total product sales for Q3 2025 were $7.3 billion, while the company generated $4.1 billion in operating cash flow that same quarter.

Government agencies and NGOs focused on global health are essential for access in lower-income settings. Gilead has a plan to supply lenacapavir doses for 2 million people across three years in these regions, equating to 666,000 people annually. In South Africa, a broader rollout is expected to start with 400,000 doses received through a deal with the Global Fund to Fight AIDS. The US cost for this preventative is around $28,000 a year.

Here is a snapshot of the revenue contribution from the core product segments for Q3 2025:

Customer Segment Focus	Product/Area	Q3 2025 Sales Amount	Year-over-Year Change
Patients with HIV (Treatment)	Biktarvy	$3.7 billion	+6%
Patients with HIV (Prevention/PrEP)	Descovy	$701 million	+20%
Patients with HIV (Prevention/PrEP)	Yeztugo (YTD)	$54 million	N/A
Oncology patients (mTNBC/HR+)	Trodelvy	$293 million	-5%
Patients with Liver Diseases (HBV/HDV/PBC)	Liver Disease Portfolio	$819 million	+12%

The needs of these customer segments drive Gilead Sciences, Inc.'s strategic focus, which is reflected in the company's overall financial posture:

• Full-year 2025 product sales guidance range is between $28.4 billion and $28.7 billion.
• As of September 30, 2025, cash, cash equivalents, and marketable debt securities totaled $9.4 billion.
• The company returned $1.0 billion in dividends during Q3 2025.
• The market capitalization stood at $155B as of December 4, 2025.

For the HIV prevention segment, the focus is on expanding reach to populations not currently using PrEP, with researchers presenting strategies for the PURPOSE 5 trial in France and the UK.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Cost Structure

You're looking at the hard numbers that drive Gilead Sciences, Inc.'s operations as of late 2025. The cost structure is heavily weighted toward innovation and getting those innovations to market globally. Here's a breakdown of the key expense areas based on the latest reported figures.

High R&D expenditure, with $1.3 billion spent in Q3 2025

Research and development (R&D) remains a massive cost center, showing the company's commitment to pipeline advancement. For the third quarter of 2025, R&D expenses clocked in at $1.3 billion. This was actually a decrease from the prior year's Q3, primarily due to lower study-related and clinical manufacturing expenses. Year-to-date 2025 R&D expenses were reported at $4.1 billion, which management indicated was in line with 2024 performance for the same period. Management expects full-year 2025 R&D expenses to be roughly flat on a dollar basis compared to 2024.

Significant Selling, General, and Administrative (SG&A) costs for global commercialization

Moving product is expensive, and Gilead Sciences, Inc.'s global footprint requires substantial SG&A spending. In the third quarter of 2025, SG&A expenses were $1.4 billion. This was down 4% compared to the third quarter of 2024, partly due to lower corporate expenses, though this was partially offset by higher HIV promotional expenses. For the twelve months ending September 30, 2025, total SG&A expenses reached $5.886 billion. The expectation for the full year 2025 was a decline in SG&A expenses by a mid to high single-digit percentage compared to 2024's total of $6.091 billion. That's real money spent on sales forces and administrative overhead.

Here's a quick look at how those key operating expenses stacked up for the first three quarters of 2025:

Period	R&D Expenses (GAAP)	SG&A Expenses (GAAP)
Q1 2025	$1.4 billion	$1.3 billion
Q2 2025	$1.5 billion	$1.4 billion
Q3 2025	$1.3 billion	$1.4 billion
Year-to-Date 2025	$4.1 billion	Not explicitly provided as YTD sum

Costs of Revenue, including raw material procurement and complex manufacturing

The cost to actually produce the drugs is managed tightly, reflected in the gross margin figures. Product gross margin for the third quarter of 2025 was 78.6%. On a non-GAAP basis, which strips out certain items, the product gross margin was 86.5% in Q3 2025. This margin performance is what drives the underlying cost of sales, which is a direct reflection of raw material procurement and the complexity of manufacturing these specialized therapies. The non-GAAP product gross margin for the twelve months ending September 30, 2025, was also guided to be around 86.5%.

Acquisition-related expenses and contingent consideration payments

Business development activity creates specific, often non-recurring, costs that hit the income statement. Acquired In-Process Research and Development (IPR&D) expenses in the third quarter of 2025 totaled $170 million. This Q3 figure included a $120 million upfront payment related to the collaboration with Shenzhen Pregene Biopharma Co., Ltd. For the full year 2025, acquired IPR&D was expected to be $900 million. You should note that prior periods included significant, non-repeating charges, such as the $3.9 billion IPR&D expense related to the CymaBay acquisition in Q1 2024. Furthermore, the pending Interius BioTherapeutics acquisition is expected to involve a total cash consideration of $350 million, with related charges anticipated in Q4 2025.

Key acquisition-related costs in 2025 include:

• $170 million Acquired IPR&D in Q3 2025.
• $120 million Upfront payment to Pregene in Q3 2025.
• $61 million Acquired IPR&D in Q2 2025, tied to Kymera partnership.
• Expected full year acquired IPR&D of $900 million.

Capital investment in new U.S. manufacturing and research facilities

Capital expenditures (CAPEX) reflect the investment in the physical assets needed to support future operations. The forecast for Gilead Sciences, Inc.'s CAPEX for the full fiscal year 2025 was set at $568.6 million. This figure represents the planned spending on property, plant, and equipment, which would encompass investments in new or expanded U.S. manufacturing and research facilities, though specific facility spending isn't itemized in the top-line reports. Finance: draft 13-week cash view by Friday.

Gilead Sciences, Inc. (GILD) - Canvas Business Model: Revenue Streams

Gilead Sciences, Inc. projects total full-year 2025 product sales to be between $28.4 billion and $28.7 billion.

The dominant HIV franchise remains the cornerstone, delivering $5.3 billion in sales for the third quarter of 2025, representing a 4% increase year-over-year. This growth was driven by both Biktarvy and Descovy performance. The company anticipates its full-year HIV franchise revenue growth to be approximately 5%, despite an expected $900 million headwind from the Medicare Part D redesign in 2025.

The revenue streams from Gilead Sciences, Inc. product sales in the third quarter of 2025 are detailed below:

Product/Franchise Segment	Q3 2025 Revenue (USD)
HIV Product Sales	$5.3 billion
Veklury (remdesivir) Sales	$277 million
Oncology - Cell Therapies Total	$432 million
Oncology - Trodelvy Sales	$357 million
Oncology - Yescarta Sales	$349 million
Oncology - Tecartus Sales	$83 million

The Oncology segment includes the Cell Therapies, which totaled $432 million in Q3 2025 sales, reflecting an 11% decrease compared to the same period in 2024. Trodelvy sales specifically grew 7% to $357 million in the third quarter of 2025. The Cell Therapy sales breakdown includes Yescarta at $349 million and Tecartus at $83 million for the quarter.

Royalty, contract, and other revenues contributed approximately $400 million in the third quarter of 2025, an increase compared to the same period in 2024, primarily due to revenue related to a previous sale of intellectual property not expected to reoccur.

Sales of Veklury (remdesivir) are declining as expected due to lower rates of COVID-19-related hospitalizations, recording $277 million in the third quarter of 2025, a 60% decrease year-over-year. The company continues to expect full-year Veklury revenue of approximately $1 billion.

Further detail on the key drivers within the HIV franchise for Q3 2025 includes:

• Biktarvy sales: $3.7 billion, up 6% year-over-year.
• Descovy sales: $701 million, up 20% year-over-year.
• New HIV prevention product (Yes2Go) sales: $39 million for the third quarter, with $54 million including initial launch weeks in June.